What's Happening?
Marea Therapeutics has enrolled the first patient in its Phase 2b TYDAL-TIMI 78 clinical study, which evaluates the drug MAR001 in adults at risk of atherosclerotic cardiovascular disease (ASCVD). MAR001 is a monoclonal antibody designed to block the activity of ANGPTL4, a protein expressed in adipose tissue, and is delivered via subcutaneous injection. The study aims to enroll approximately 216 patients, who will be randomized to receive MAR001 or a placebo every four weeks for 24 weeks. The primary endpoints will assess changes in fasting triglycerides and remnant cholesterol levels. Secondary endpoints include changes in very low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol. The study is led by Marc S. Sabatine, M.D., M.P.H., and aims to address unmet needs in patients with ASCVD.
AD
Why It's Important?
The initiation of this study is significant as it targets a major unmet need in cardiovascular health, focusing on patients with persistently high triglycerides and remnant cholesterol levels. These factors contribute to elevated cardiovascular risk, and MAR001 offers a novel approach by targeting ANGPTL4. If successful, this trial could lead to a new class of therapies that reduce residual cardiovascular risk, potentially improving outcomes for patients with cardiometabolic diseases. The study's results could shift the treatment paradigm, offering precision therapy for patients who remain at risk despite traditional factor control.
What's Next?
The study is expected to produce topline results by mid-2026. Marea Therapeutics is advancing MAR001 into this Phase 2b trial with the aim of generating data that could change the treatment landscape for cardiometabolic diseases. The company is focused on moving this innovative therapy closer to patients, potentially offering a new precision treatment option for those with elevated residual cardiovascular risk.
